Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian for Stroke Prevention After Acute Ischemic Stroke or High-Risk TIA
NCT05702034Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 47
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and Transient Ischemic Attack (TIA) comparing Milvexian + Antiplatelet Therapy with Placebo + Antiplatelet Therapy (2 arms). Primary endpoint: Time to First Occurrence of Ischemic Stroke at 41 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
milvexian
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT05702034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702034.